Core Insights - Corbus Pharmaceuticals Holdings, Inc. provided a corporate update and reported financial results for Q1 2025, highlighting advancements in its oncology and obesity pipeline [1][2]. Corporate and Program Updates - The company presented promising Phase 1 data for CRB-701, an antibody drug conjugate targeting Nectin-4, at ASCO GU [2][3]. - CRB-913, an oral small molecule designed for obesity treatment, initiated its Phase 1 study in March 2025, with completion expected in Q3 2025 [4]. - CRB-601, an anti-αvβ8 integrin monoclonal antibody, is in a Phase 1 study with completion anticipated in Q4 2025 [5][6]. - The FDA granted Fast Track designation to CRB-701 for treating relapsed or refractory metastatic cervical cancer [7]. Financial Results - For the quarter ended March 31, 2025, the company reported a net loss of approximately $17.0 million, compared to a net loss of $6.9 million for the same period in 2024 [8]. - Operating expenses increased by $10.2 million to approximately $19.8 million, primarily due to clinical development expenses [9]. - As of March 31, 2025, the company had $132.8 million in cash and investments, expected to fund operations through Q2 2027 [9].